10 April 2018 - - Paris, France-based synthetic nucleic acids provider DNA Script has received awards totaling USD 5.5m in non-dilutive financing from the Horizon 2020 European Innovation Council program of the European Commission and the Aide au développement de l'innovation and Concours Mondial d'innovation programs of Bpifrance investment bank, the company said.
DNA Script was awarded this financing, to be received as subsidies and refundable advances, based on the promise of the company's innovative enzymatic DNA synthesis technology and its potential to become a leader in DNA and RNA manufacturing.
DNA Script's biochemical process for DNA and RNA synthesis is based on the use of highly efficient enzymes. This technology mimics the way nature produces genetic code and enables enhanced performance while minimizing the use of harsh chemicals.
DNA Script is one of 57 companies to receive the very first award for small and medium-sized businesses given by the recently established European Innovation Council -- a funding, advisory and networking arm of Horizon 2020 intended to support leading innovators, entrepreneurs, small companies and scientists.
DNA Script manufactures de novo synthetic nucleic acids using an enzymatic technology.
The company aims to accelerate innovation in life sciences and technology through rapid, affordable and high-quality DNA synthesis. The company's technology has the potential to greatly accelerate the development of new therapeutics, sustainable chemical production, improved crops and DNA data storage.